Lv41
510 积分 2021-12-16 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
4天前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
13天前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
1个月前
已完结
Local Consolidative Therapy in Lung Cancer
2个月前
已完结
Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer
2个月前
已完结
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
2个月前
已关闭
Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer
2个月前
已完结
Molecular Profiling across 80,000 Patients with Lung Cancer
2个月前
已完结
皖公网安备34019202002308
